BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

147 related articles for article (PubMed ID: 34547645)

  • 1. Double-edged Swords: Diaryl pyrazoline thiazolidinediones synchronously targeting cancer epigenetics and angiogenesis.
    Upadhyay N; Tilekar K; Safuan S; Kumar AP; Schweipert M; Meyer-Almes FJ; Ramaa CS
    Bioorg Chem; 2021 Nov; 116():105350. PubMed ID: 34547645
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Development and investigation of thiazolidinedione and pyrazoline compounds as antiangiogenic weapons targeting VEGFR-2.
    Upadhyay N; Tilekar K; Safuan S; Kumar AP; Schweipert M; Meyer-Almes FJ; Ramaa CS
    Future Med Chem; 2021 Nov; 13(22):1963-1986. PubMed ID: 34581188
    [No Abstract]   [Full Text] [Related]  

  • 3. Effect of phenylurea hydroxamic acids on histone deacetylase and VEGFR-2.
    Lee S; Wang SW; Yu CL; Tai HC; Yen JY; Tuan YL; Wang HH; Liu YT; Chen SS; Lee HY
    Bioorg Med Chem; 2021 Nov; 50():116454. PubMed ID: 34634618
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Discovery of novel tubulin/HDAC dual-targeting inhibitors with strong antitumor and antiangiogenic potency.
    Wang Y; Sun M; Wang Y; Qin J; Zhang Y; Pang Y; Yao Y; Yang H; Duan Y
    Eur J Med Chem; 2021 Dec; 225():113790. PubMed ID: 34454126
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pyrazolo-benzothiazole hybrids: Synthesis, anticancer properties and evaluation of antiangiogenic activity using in vitro VEGFR-2 kinase and in vivo transgenic zebrafish model.
    Reddy VG; Reddy TS; Jadala C; Reddy MS; Sultana F; Akunuri R; Bhargava SK; Wlodkowic D; Srihari P; Kamal A
    Eur J Med Chem; 2019 Nov; 182():111609. PubMed ID: 31445229
    [TBL] [Abstract][Full Text] [Related]  

  • 6. AR-42: A Pan-HDAC Inhibitor with Antitumor and Antiangiogenic Activities in Esophageal Squamous Cell Carcinoma.
    Zhu Y; Yuan T; Zhang Y; Shi J; Bai L; Duan X; Tong R; Zhong L
    Drug Des Devel Ther; 2019; 13():4321-4330. PubMed ID: 31908417
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A novel 2-aminobenzimidazole-based compound Jzu 17 exhibits anti-angiogenesis effects by targeting VEGFR-2 signalling.
    Lien JC; Chung CL; Huang TF; Chang TC; Chen KC; Gao GY; Hsu MJ; Huang SW
    Br J Pharmacol; 2019 Oct; 176(20):4034-4049. PubMed ID: 31368127
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Discovery of Novel Pazopanib-Based HDAC and VEGFR Dual Inhibitors Targeting Cancer Epigenetics and Angiogenesis Simultaneously.
    Zang J; Liang X; Huang Y; Jia Y; Li X; Xu W; Chou CJ; Zhang Y
    J Med Chem; 2018 Jun; 61(12):5304-5322. PubMed ID: 29787262
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Discovery of novel anti-angiogenesis agents. Part 7: Multitarget inhibitors of VEGFR-2, TIE-2 and EphB4.
    Li C; Shan Y; Sun Y; Si R; Liang L; Pan X; Wang B; Zhang J
    Eur J Med Chem; 2017 Dec; 141():506-518. PubMed ID: 29102175
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Exploration of carbamide derived pyrimidine-thioindole conjugates as potential VEGFR-2 inhibitors with anti-angiogenesis effect.
    Sana S; Reddy VG; Bhandari S; Reddy TS; Tokala R; Sakla AP; Bhargava SK; Shankaraiah N
    Eur J Med Chem; 2020 Aug; 200():112457. PubMed ID: 32422489
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Novel dual inhibitors targeting CDK4 and VEGFR2 synergistically suppressed cancer progression and angiogenesis.
    Huang Z; Zhao B; Qin Z; Li Y; Wang T; Zhou W; Zheng J; Yang S; Shi Y; Fan Y; Xiang R
    Eur J Med Chem; 2019 Nov; 181():111541. PubMed ID: 31382120
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Design, synthesis and biological evaluation of novel thioquinazolinone-based 2-aminobenzamide derivatives as potent histone deacetylase (HDAC) inhibitors.
    Cheng C; Yun F; He J; Ullah S; Yuan Q
    Eur J Med Chem; 2019 Jul; 173():185-202. PubMed ID: 31003060
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Design, synthesis, molecular docking, anticancer evaluations, and in silico pharmacokinetic studies of novel 5-[(4-chloro/2,4-dichloro)benzylidene]thiazolidine-2,4-dione derivatives as VEGFR-2 inhibitors.
    El-Adl K; El-Helby AA; Sakr H; Ayyad RR; Mahdy HA; Nasser M; Abulkhair HS; El-Hddad SSA
    Arch Pharm (Weinheim); 2021 Feb; 354(2):e2000279. PubMed ID: 33073374
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Oleanolic Acid Inhibits Colorectal Cancer Angiogenesis by Blocking the VEGFR2 Signaling Pathway.
    Niu G; Sun L; Pei Y; Wang D
    Anticancer Agents Med Chem; 2018; 18(4):583-590. PubMed ID: 29065844
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Discovery of novel thiophene-3-carboxamide derivatives as potential VEGFR-2 inhibitors with anti-angiogenic properties.
    Li T; Wang J; Feng L; Zhou Q; Xie Q; Shen Y; Ji R; Liu X; Wang Y; Hu C
    Bioorg Chem; 2024 Jun; 147():107358. PubMed ID: 38626490
    [TBL] [Abstract][Full Text] [Related]  

  • 16. New thiazolidine-2,4-diones as potential anticancer agents and apoptotic inducers targeting VEGFR-2 kinase: Design, synthesis, in silico and in vitro studies.
    Elkady H; Mahdy HA; Taghour MS; Dahab MA; Elwan A; Hagras M; Hussein MH; Ibrahim IM; Husein DZ; Elkaeed EB; Alsfouk AA; Metwaly AM; Eissa IH
    Biochim Biophys Acta Gen Subj; 2024 Jun; 1868(6):130599. PubMed ID: 38521471
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Discovery of novel anti-angiogenesis agents. Part 8: Diaryl thiourea bearing 1H-indazole-3-amine as multi-target RTKs inhibitors.
    Sun Y; Shan Y; Li C; Si R; Pan X; Wang B; Zhang J
    Eur J Med Chem; 2017 Dec; 141():373-385. PubMed ID: 29032031
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Quinazoline-based multi-tyrosine kinase inhibitors: synthesis, modeling, antitumor and antiangiogenic properties.
    Conconi MT; Marzaro G; Urbani L; Zanusso I; Di Liddo R; Castagliuolo I; Brun P; Tonus F; Ferrarese A; Guiotto A; Chilin A
    Eur J Med Chem; 2013 Sep; 67():373-83. PubMed ID: 23900004
    [TBL] [Abstract][Full Text] [Related]  

  • 19. New benzothiazole/thiazole-containing hydroxamic acids as potent histone deacetylase inhibitors and antitumor agents.
    Tung TT; Oanh DT; Dung PT; Hue VT; Park SH; Han BW; Kim Y; Hong JT; Han SB; Nam NH
    Med Chem; 2013 Dec; 9(8):1051-7. PubMed ID: 23521008
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Synthesis, molecular docking and evaluation of thiazolyl-pyrazoline derivatives as EGFR TK inhibitors and potential anticancer agents.
    Lv PC; Li DD; Li QS; Lu X; Xiao ZP; Zhu HL
    Bioorg Med Chem Lett; 2011 Sep; 21(18):5374-7. PubMed ID: 21802290
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.